Vyne Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

YARROW BIOSCIENCE

12/05/2022 23:53

* Vyne Therapeutics Inc  VYNE.OQ  reported a quarterly
adjusted
loss of 14 cents​​ per share for the quarter ended in March. The
mean expectation of four analysts for the quarter was for a loss
of 16 cents per share.
    * Revenue fell 95.7% to $178.00 thousand from a year ago; 
analysts expected $366.67 thousand. 
    * Vyne Therapeutics Inc's reported EPS for the quarter was 8
cents​.
    * The mean earnings estimate of analysts had fallen by
about 10%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Vyne Therapeutics Inc shares had fallen by 41.7% this
quarter and lost 62.8% so far this year.
    * The company reported quarterly net income of $4.67
million.
    * Wall Street's median 12-month price target for Vyne
Therapeutics
Inc is $5.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 12 at 10:52 p.m.  ​All
figures in US dollars unless otherwise stated